Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

This study has been completed.
Sponsor:
Information provided by:
HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:
NCT00481260
First received: May 31, 2007
Last updated: September 3, 2009
Last verified: September 2009
  Purpose

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.


Condition Intervention
Hgb C Hemoglobinopathy
Procedure: Medical history and basic laboratory analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Further study details as provided by HaEmek Medical Center, Israel:

Estimated Enrollment: 100
Study Start Date: May 2007
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Medical history and basic laboratory analysis
    Medical history and basic laboratory analysis
Detailed Description:

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed at the pediatric Hematology Unit of laboratory data from the thalassemia screening in northern Israel

Criteria

Inclusion Criteria:

  • All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00481260

Locations
Israel
Pediatric Hematology Unit - HaEmek Medical Center
Afula, Israel, 18101
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Study Director: Ariel Koren, MD Pediatric Hematology Unit, Ha'Emek Medical Center
Study Chair: luci Zalman, Phd Hematology Laboratory - HaeEmek Medical Center
  More Information

No publications provided

Responsible Party: Dr Koren Ariel, Pediatric Hematology Unit - HaEmek Medical Center - Afula - Israel
ClinicalTrials.gov Identifier: NCT00481260     History of Changes
Other Study ID Numbers: 5100706.EMC
Study First Received: May 31, 2007
Last Updated: September 3, 2009
Health Authority: Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:
Hgb C
Screening

Additional relevant MeSH terms:
Hemoglobinopathies
Hematologic Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on April 14, 2014